Nuanyang Medical Completes Nearly RMB 100 Million Series A and A+ Financing to Advance Innovative Neurovascular Intervention Products

Nuanyang Medical Officially Announces Completion of Nearly RMB 100 Million in Series A and A+ FinancingJiangsu Nuanyang Medical Instrument Co., Ltd. (hereinafter referred to as “Nuanyang Medical”) has officially announced that it recently completed nearly RMB 100 million in Series A and A+ financing. The Series A round was led by DaoTong Investment, with participation from Fengshuo Venture Capital, existing shareholder Huachuang Capital, and Rongan Venture Capital. The Series A+ round was led by Yijing Capital, with continued participation from DaoTong Investment. China Renaissance served as the exclusive financial advisor for this financing round. Following this round of financing, the company will advance its core neurointerventional products into the registration-related clinical trial stage and accelerate the research and development of its product pipeline in other therapeutic areas.

Nuanyang Medical, established in 2019, focuses on the field of neurointervention and boasts a comprehensive product pipeline covering hemorrhagic, ischemic, and access solutions. Its product portfolio includes flow diversion systems, thrombectomy stents, aspiration catheters, balloon catheters, and microcatheters. Among these, its flagship flow diversion system provides full coverage of indications from small to giant aneurysms, with core performance metrics leading globally. Another key product line, comprising thrombectomy stents and aspiration catheters, represents a global first by ensuring adequate thrombectomy efficacy while reducing intraoperative risks.

Jia Jing, founder of Nuanyang Medical, stated, “We extend our gratitude to both new and existing investors for their support and recognition. This round of financing will accelerate the development of our core products. We believe that the next decade represents a ‘golden era’ for neurointerventional medicine. Nuanyang Medical’s comprehensive layout across the three major domains of neurointervention—hemorrhagic stroke, ischemic stroke, and vascular access—holds significant importance for advancing the prevention and treatment of stroke in China and globally. Committed to original innovation, we have achieved substantial breakthroughs in every aspect of product design based on a thorough understanding of clinical pain points, earning positive feedback and high acclaim from clinicians. We prioritize product quality, conducting rigorous evaluations throughout the design and development phases. At Nuanyang Medical, our goal is to create products with ‘warmth.’”

Sun Qi, Founding Managing Partner of DaoTong Investment, stated, “We are delighted to participate as the lead investor in Nuanyang Medical’s Series A financing round. China has a very large base of stroke patients, with nearly 30 million currently affected and over one million new cases annually, making stroke the leading cause of death in the country. This vast market with rigid demand exhibits an extremely high appetite for high-quality innovative products. Companies with comprehensive product lineups and genuine innovative advantages are better positioned to compete in the market. Nuanyang Medical is precisely such a company, possessing the capacity for continuous self-transcendence and disruptive innovation through iterative development. Therefore, we are optimistic about the company’s future and look forward to seeing it deliver more breakthroughs in the near future, helping to usher the neurointerventional industry into a new chapter.”

Yijing Capital stated, “Nuanyang Medical is a leading enterprise in China’s neurointerventional industry. Its core team possesses both R&D capabilities in cardiovascular and cerebrovascular medical devices and extensive experience in management and sales. We highly recognize the team’s innovation and execution capabilities. We are delighted to support the company’s growth and, with additional resources, hope that Nuanyang Medical will leverage its existing multi-pipeline R&D and innovation strengths to accelerate the development and market launch of its products. In becoming a leader in the neurointerventional sector, the company will also contribute to the prevention and treatment of stroke in China.”

Yang Jin, project leader at Fengshuo Venture Capital, stated, “We established an early connection with Nuanyang Medical and have consistently monitored the company’s development. We are pleased to leverage our resources to support the enterprise. We are optimistic about Nuanyang Medical’s sustained R&D innovation capabilities and its ability to advance projects, and we look forward to the early market launch of its products to enrich China’s neurointerventional market.”

Xiong Weiming, Partner at Huachuang Capital, stated, “Nuanyang is clinically driven and demonstrates strong innovation in its portfolio of neurointerventional products. It has also taken a forward-looking approach to pharmaceutical-device synergy and the design of next-generation neurointerventional devices. We look forward to Nuanyang continuously delivering better products to clinicians and patients.”

Xin Xiaoxiong, Investment Director at Rongan Venture Capital, stated, “China has a high incidence of cerebrovascular disease, with the number of new cases rising year by year. However, treatment options available to patients are limited and have long relied on imports. Addressing these product gaps and benefiting a broad patient population was the original intention behind Mr. Jia and his team in founding Nuanyang Medical. We are delighted to have witnessed and accompanied Nuanyang Medical’s growth and development along the way. We firmly believe that the company will continue to provide safe, effective, and affordable innovative products for patients in China, contributing to the acceleration of self-sufficiency and controllability in China’s high-end medical device sector.”

Zhou Xiang, Head of the Financial Advisory Division at China Renaissance, stated, “The neurointerventional industry is a sector we have been closely monitoring. We are honored to have assisted Nuanyang Medical in completing this landmark private equity financing transaction. Nuanyang Medical boasts globally leading innovative technologies and a robust product pipeline. Its team combines visionary strategic planning with pragmatic execution capabilities. We look forward to Nuanyang Medical’s advancements in the field of neurointervention, which will drive progress in the global prevention and treatment of stroke, benefiting more patients.”